Stifel analyst Annabel Samimy reiterated a Buy rating and $210.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) as Nabiximols trials ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE